Comparison · NCT00128102-sae
Vorinostat vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vorinostat vs Placebo: serious adverse events. Trial comparisons, record NCT00128102-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00128102-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.404 | 0.353 | 0.458 | wilson | |
| Risk in group 2 | 0.398 | 0.347 | 0.452 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00608 | -0.0685 | 0.0805 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.842 | 1.22 | log | |
| Odds ratio, group 1 over group 2 | 1.03 | 0.751 | 1.4 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Vorinostat than on Placebo | 165 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vorinostat | Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment continued until disease progression or unacceptable toxicity. | 133 | 329 | EG000 |
| Group 2 | Placebo | Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment continued until disease progression or unacceptable toxicity. | 131 | 329 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to ~77 months (through database cut-off date of 21-November-2011)
Source ClinicalTrials.gov
Trial
- Title
- Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)
- NCT number
- NCT00128102
- Phases
- PHASE3
- Conditions
- Mesothelioma, Lung Cancer
- Interventions
- Vorinostat, Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2020-10-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00128102?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00128102-sae